Fundraising FoxSulfagenix
Chesterland, US · Founded 2011 · Delaware corporation
Find your way into Sulfagenix
Sign up to see every warm intro you have to Sulfagenix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sulfagenix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sulfagenix develops SG1002, an oral hydrogen sulfide prodrug designed to treat oxidative stress-related diseases including cardiovascular disorders, cancer, and other chronic conditions. The company targets patients with conditions ranging from heart failure to cancer, diabetes, and neurodegeneration.
Founders & leadership
Sulfagenix was founded in 2011 by Gabriel Gojon-Romanillos and Gabriel Gojon-Zorrilla.
GG
Gabriel Gojon-RomanillosCo-founder
GG
Gabriel Gojon-ZorrillaCo-founder, Head of R&D
DG
Dr. Guillermo A. MoralesCOO & Scientific Advisory Board Coordinator
AT
Anthony T. GiordanoFormer President and CEO
Board
GG
Gabriel Gojon, Jr.Board director
CV
Cesar VidalesChairman
Reported raises · per SEC filings
Form D private placements$2.6M disclosed across 2 rounds · 2014
▶$1.3MraisedDec 2016 · 2 investors · BiotechnologyRule 506(b)
▶$1.3MraisedDec 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony GiordanoExecutive Officer, Director
- Gabriel Gojon, Jr.Director
- Cesar VidalesDirector
- Offering amount
- $1.6M
- Amount sold
- $1.3M
- Minimum investment
- $10K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$1.3MraisedMar 2014 · 2 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedMar 2014 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gabriel Gojon, Jr.Director
- Anthony GiordanoExecutive Officer, Director
- Cesar VidalesDirector
- Offering amount
- $3M
- Amount sold
- $1.3M
- Minimum investment
- $100K
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Sulfagenix do?
- Sulfagenix develops SG1002, an oral hydrogen sulfide prodrug designed to treat oxidative stress-related diseases including cardiovascular disorders, cancer, and other chronic conditions. The company targets patients with conditions ranging from heart failure to cancer, diabetes, and neurodegeneration.
- Who founded Sulfagenix?
- Sulfagenix was founded by Gabriel Gojon-Romanillos, Gabriel Gojon-Zorrilla in 2011.
- How much funding has Sulfagenix raised?
- Sulfagenix has disclosed $2.6M raised across 2 rounds.
- Where is Sulfagenix headquartered?
- Sulfagenix is headquartered in Chesterland, US.